metaEvidence

	atezolizumab based treatment	anti-PD-(L)1	durvalumab based treatment	nivolumab based treatment	pembrolizumab based treatment	Immune checkpoint association
	atezolizumab alone	cemiplimab	durvalumab alone	nivolumab alone	pembrolizumab alone	durvalumab plus tremelimumab	nivolumab plus ipilimumab	pembrolizumab plus ipilimumab
mNSCLC - L1 - PDL1 positive 14

Comparator: vs Standard of Care (SoC); vs pemetrexed plus platin; vs pembrolizumab plus placebo;
Risk of bias: low; some concerns; high; NA;